Podcast Episodes
Back to Search
Ep. 118 - Regeneron's Gonçalo Abecasis on turning genetic data into drug targets
Season 5 Episode 118
On This Edition of The BioCentury Show, Gonçalo Abecasis, SVP and Chief Genomics and Data Sciences Officer at the Regeneron Genetics Center, joins Bi…
14 hours ago
Ep. 117 - C-Path's Klaus Romero on moving genetic medicines beyond one patient
Season 5 Episode 117
The Critical Path Institute’s One to Millions Initiative is using individualized rare disease therapies as the starting point for a development frame…
2 weeks ago
Ep. 116 - Ovid's Jeremy Levin on biotech in the balance
Season 5 Episode 116
Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small bio…
4 weeks ago
Ep. 115 - Initiate's Owens on what it takes to be AI-native
Season 5 Episode 115
As AI becomes increasingly commoditized, Initiate Ventures' Jessica Owens argues healthcare and life sciences companies need to use it to solve histo…
1 month, 1 week ago
Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model
Season 5 Episode 114
Roivant CEO Matt Gline calls the company’s move beyond spinning out subsidiary “vants” to concentrating on late-stage programs and commercial launche…
1 month, 3 weeks ago
Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking
Season 5 Episode 113
Launched in the 1970s as a generics company, Hengrui has become China’s leading innovator in R&D and dealmaking, with more than 100 NMEs in the pipel…
2 months, 1 week ago
Ep. 112 - Chris Arendt on rebuilding Takeda for AI
Season 5 Episode 112
Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while …
2 months, 2 weeks ago
Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner
Season 5 Episode 111
ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the…
2 months, 3 weeks ago
Ep. 110 - Richard Pops on Three Decades in Biotech: Drug pricing, FDA and China
Season 5 Episode 110
Richard Pops has lived the biotech roller coaster over three decades as CEO of Alkermes: an IPO, M&A, near-death events for his company, FDA setbacks…
3 months ago
Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development
Season 5 Episode 109
Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a …
3 months, 2 weeks ago